MetaCap

Enovis Corporation (ENOV)

NYSE: ENOVHealth CareIndustrial SpecialtiesUSD

25.47-0.76 (-2.90%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ENOV stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$9.23
52-week range
16.70 – 31.67
Day range
25.39 – 26.62
Volume / Avg
1.22M / 1.71M
Beta
—

52-week range

$16.70$31.67

ENOV stock today

Shares of Enovis (ENOV) finished lower on Nov 20 at $25.47, a drop of 2.90% or $0.76 per share, versus the S&P 500's 3.70% decline. At this level, ENOV sits in the middle of its 52-week range of $16.70 to $31.67: 19.6% below the high, set on Aug 4, 2026 and 52.5% above the low. ENOV is down 4.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 11.5%.

Enovis has posted a net loss over the last twelve months (EPS of -$9.23), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Enovis

Company profile

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions.

Industry
Industrial Specialties
CEO
Mr. Damien McDonald
Headquarters
Lewisville, TX
Employees
7,802
Website
enovis.com

Financial highlights

Full financials

In fiscal 2025, Enovis generated $2.25 billion in revenue, up 6.7% from fiscal 2024, its 5th consecutive year of revenue growth. Enovis reported a net loss of $1.18 billion, compared with a loss of $825.5 million a year earlier. Gross margin was 59.8% (up from 56.0%) and operating margin -50.0%.

Enovis annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.25B$2.11B$1.71B$1.56B$1.43B
Growth+6.66%+23.46%+9.22%+9.60%+27.26%
Net income$-1.18B$-825.49M$-33.26M$-13.29M$71.66M
EPS (diluted)$-20.75$-14.93$-0.61$-0.25$1.40

Analyst forecast

Forecast

Consensus (13 analysts)

strong_buy

Avg. price target

$37.83+48.53%

  • Strong buy 2
  • Buy 10
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $27.00High $47.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.06 vs $0.64
Surprise
-90.63%

ENOV news

All ENOV news

Enovis peers

Health Care sector
ENOV peer companies
CompanyPrice% ChgMarket capCompare
DSGRDistribution Solutions Group Inc.35.00-0.09%$1.62Bvs ENOV
TRSTriMas Corporation36.77-2.52%$1.30Bvs ENOV
CDRECadre Holdings Inc.29.45-3.63%$1.26Bvs ENOV
XPELXPEL Inc.38.12+1.36%$1.05Bvs ENOV
FOILLondian Wason New Energy Tech Inc. ADR12.30-11.95%$969.05Mvs ENOV
WLFCWillis Lease Finance Corporation41.96-2.31%$957.23Mvs ENOV
ESTAEstablishment Labs Holdings Inc.69.14-0.68%$2.06Bvs ENOV
ADSEADS-TEC ENERGY PLC9.78+3.82%$735.32Mvs ENOV

Indexes, lists and sector

Enovis stock FAQ

What is Enovis's stock price today?

ENOV last traded at $25.47 as of Nov 20, 4:00 PM EST, down 2.90% on the day. Prices are delayed at least 15 minutes.

Does Enovis pay a dividend?

No. Enovis does not currently pay a regular cash dividend.

Who is Enovis's CEO?

Mr. Damien McDonald is the chief executive officer of Enovis Corporation, which has about 7,802 employees.

Has ENOV ever split its stock?

Yes. The most recent ENOV stock split was a 581-for-1000 split on Apr 5, 2022.

What is the ENOV 52-week high?

The 52-week high for ENOV is $31.67 and the 52-week low is $16.70. The stock is currently 19.6% below its high.

Compare ENOV